127 related articles for article (PubMed ID: 38796564)
1. Population Pharmacokinetics of Bepirovirsen in Healthy Participants and Participants with Chronic Hepatitis B Virus Infection: Results from Phase 1, 2a, and 2b Studies.
Youssef AS; Ismail M; Han K; Magee M; Nader A
Infect Dis Ther; 2024 May; ():. PubMed ID: 38796564
[TBL] [Abstract][Full Text] [Related]
2. B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection.
Cremer J; Elston R; Campbell FM; Kendrick S; Paff M; Quinn G; Theodore D
Adv Ther; 2023 Sep; 40(9):4101-4110. PubMed ID: 37393402
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
Yuen MF; Heo J; Jang JW; Yoon JH; Kweon YO; Park SJ; Tami Y; You S; Yates P; Tao Y; Cremer J; Campbell F; Elston R; Theodore D; Paff M; Bennett CF; Kwoh TJ
Nat Med; 2021 Oct; 27(10):1725-1734. PubMed ID: 34642494
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus-Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses.
Han K; Theodore D; McMullen G; Swayze E; McCaleb M; Billioud G; Wieland S; Hood S; Paff M; Bennett CF; Kwoh TJ
Clin Pharmacol Drug Dev; 2022 Oct; 11(10):1191-1202. PubMed ID: 35971951
[TBL] [Abstract][Full Text] [Related]
5. Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress.
Mak LY; Hui RW; Fung J; Seto WK; Yuen MF
Expert Opin Investig Drugs; 2023; 32(11):971-983. PubMed ID: 37902953
[TBL] [Abstract][Full Text] [Related]
6. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
Yuen MF; Heo J; Kumada H; Suzuki F; Suzuki Y; Xie Q; Jia J; Karino Y; Hou J; Chayama K; Imamura M; Lao-Tan JY; Lim SG; Tanaka Y; Xie W; Yoon JH; Duan Z; Kurosaki M; Park SJ; Labio ME; Kumar R; Kweon YO; Yim HJ; Tao Y; Cremer J; Elston R; Davies M; Baptiste-Brown S; Han K; Campbell FM; Paff M; Theodore D
J Hepatol; 2022 Oct; 77(4):967-977. PubMed ID: 35714812
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Pharmacokinetics of the GalNAc-Conjugated Antisense Oligonucleotide GSK3389404 in Participants with Chronic Hepatitis B Infection across the Asia-Pacific Region.
Han K; Ito H; Elston R; Cremer J; Hood S; Paff M; Theodore D
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0090022. PubMed ID: 36507675
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
Shen T; James DE; Krueger KA
Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
Narwal R; Roskos LK; Robbie GJ
Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Exposure-Response Relationships of Naldemedine.
Kubota R; Fukumura K; Wajima T
Pharm Res; 2018 Oct; 35(11):225. PubMed ID: 30280262
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection.
Chan P; Li H; Zhu L; Bifano M; Eley T; Osawa M; Ueno T; Hughes E; Bertz R; Garimella T; AbuTarif M
Clin Pharmacokinet; 2017 Oct; 56(10):1173-1183. PubMed ID: 28066880
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN).
Yang S; Lee LA; Sule N; Fowler A; Peachey G
Clin Pharmacokinet; 2021 Jul; 60(7):887-896. PubMed ID: 33598874
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females.
Pillai G; Gieschke R; Goggin T; Barrett J; Worth E; Steimer JL
Int J Clin Pharmacol Ther; 2006 Dec; 44(12):655-67. PubMed ID: 17190376
[TBL] [Abstract][Full Text] [Related]
15. A population pharmacokinetic study to accelerate early phase clinical development for a novel drug, teriflunomide sodium, to treat systemic lupus erythematosus.
Yao X; Wu Y; Jiang J; Chen X; Liu D; Hu P
Eur J Pharm Sci; 2019 Aug; 136():104942. PubMed ID: 31154006
[TBL] [Abstract][Full Text] [Related]
16. Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.
Brennan BJ; Lemenuel-Diot A; Snoeck E; McKenna M; Solsky J; Wat C; Mallalieu NL
Br J Clin Pharmacol; 2016 Apr; 81(4):658-66. PubMed ID: 26529640
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
Li YF; Combes FP; Hoch M; Lorenzo S; Sy SKB; Ho YY
Clin Pharmacokinet; 2022 Oct; 61(10):1393-1403. PubMed ID: 35764773
[TBL] [Abstract][Full Text] [Related]
18. A Population Pharmacokinetic Model of Vonoprazan: Evaluating the Effects of Race, Disease Status, and Other Covariates on Exposure.
Scarpignato C; Leifke E; Smith N; Mulford DJ; Lahu G; Facius A; Howden CW
J Clin Pharmacol; 2022 Jun; 62(6):801-811. PubMed ID: 34935142
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis.
Wojciechowski J; Malhotra BK; Wang X; Fostvedt L; Valdez H; Nicholas T
Clin Pharmacokinet; 2022 May; 61(5):709-723. PubMed ID: 35061234
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tablets.
Zhao Q; Tensfeldt TG; Chandra R; Mould DR
Malar J; 2014 Jan; 13():36. PubMed ID: 24472224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
